Heron Therapeutics, Inc. (HRTX) announced a successful Type A meeting with the FDA in which alignment was reached on the plans for the company to resubmit the New Drug Application for HTX-011 for the management of postoperative pain in the fourth quarter of current year. The company plans to resubmit the HTX-011 NDA in the next few months.

Create Account

Dark

chart

exchange

RTTNews | Sep 8, 2020 08:51AM EDT

08:51 Tuesday, September 8, 2020 (RTTNews.com) - Heron Therapeutics, Inc. (HRTX) announced a successful Type A meeting with the FDA in which alignment was reached on the plans for the company to resubmit the New Drug Application for HTX-011 for the management of postoperative pain in the fourth quarter of current year. The company plans to resubmit the HTX-011 NDA in the next few months.

"The FDA responded very positively to the information that Heron has generated to resolve the issues contained in the Complete Response Letter and agreed that the proposed specification change was acceptable," said Barry Quart, CEO of Heron.

Shares of Heron Therapeutics were up nearly 9% in pre-market trade on Tuesday.

Read the original article on RTTNews ( https://www.rttnews.com/3126869/heron-announces-alignment-with-fda-on-next-steps-for-htx-011-nda-resubmission.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved